Renal Cancer - Results from #1440

Heterogeneity of Platelet Derived Growth Factor Pathway Gene Expression Profile Defines Three Distinct Subgroups of Renal Cell Carcinomas. June 24, 2022

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. June 23, 2022

Percutaneous cryoablation for clinical T3a renal cell carcinoma (< 7 cm) with segmental vein involvement or perinephric fat invasion based on preoperative evaluation of high-resolution multidetector computed tomography scan. June 23, 2022

Aberrant MEK5 signalling promotes clear cell renal cell carcinoma development via mTOR activation. June 22, 2022

Special issue "The advance of solid tumor research in China": Presurgical therapy in the management of local retroperitoneal recurrence of renal cell carcinoma after radical nephrectomy. June 22, 2022

Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. June 21, 2022

KCNN4 may weaken anti-tumor immune response via raising Tregs and diminishing resting mast cells in clear cell renal cell carcinoma. June 21, 2022

Young age is associated with decreased recurrence for renal cell carcinoma. June 20, 2022

Bioinformatic Analysis Identifying PSMB 1/2/3/4/6/8/9/10 as Prognostic Indicators in Clear Cell Renal Cell Carcinoma. June 20, 2022

Disparity in public funding of systemic therapy for metastatic renal cell carcinoma within Canada. June 17, 2022

The Impact of Venous Thromboembolism on Mortality and Morbidity During Nephrectomy for Renal Mass. June 17, 2022

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study. June 16, 2022

Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients. June 16, 2022

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. June 15, 2022

Epigenetically-regulated miR-30a/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness. June 15, 2022

A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System (CKCis). June 14, 2022

A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. June 14, 2022

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. June 13, 2022

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. June 13, 2022

Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinoma. June 10, 2022

Page 73 of 456